Selewski, David T.
Barhight, Matthew F.
Bjornstad, Erica C.
Ricci, Zaccaria http://orcid.org/0000-0001-8916-0569
de Sousa Tavares, Marcelo
Akcan-Arikan, Ayse
Goldstein, Stuart L.
Basu, Rajit
Bagshaw, Sean M.
Alobaidi, Rashid
Askenazi, David J.
Barreto, Erin
Bayrakci, Benan
Bignall, O. N. Ray II
Brophy, Patrick
Charlton, Jennifer
Chanchlani, Rahul
Conroy, Andrea L.
Deep, Akash
Devarajan, Prasad
Dolan, Kristin
Fuhrman, Dana
Gist, Katja M.
Gorga, Stephen M.
Greenberg, Jason H.
Hasson, Denise
Heydari, Emma
Iyengar, Arpana
Jetton, Jennifer
Krawczeski, Catherine
Meigs, Leslie
Menon, Shina
Morgan, Catherine
Morgan, Jolyn
Mottes, Theresa
Neumayr, Tara
Soranno, Danielle
Stanski, Natalja
Starr, Michelle
Sutherland, Scott M.
Symons, Jordan
Vega, Molly
Zappitelli, Michael
Ronco, Claudio
Mehta, Ravindra L.
Kellum, John
Ostermann, Marlies
,
Funding for this research was provided by:
Università degli Studi di Firenze
Article History
Received: 26 June 2023
Revised: 14 August 2023
Accepted: 29 August 2023
First Online: 7 November 2023
Declarations
:
: Dr. Goldstein reported receiving personal fees from BioPorto Diagnostics, grant support and personal fees from Medtronic, Nuwellis Inc., Leadiant, personal fees from MediBeacon Inc., stock options and personal fees from Baxter Healthcare, grant support and personal fees from SeaStar Medical, and grants from ExThera Medical outside the submitted work. Dr. Akcan-Arikan reported receiving financial support for research from BioPorto research funds paid to her institution outside the submitted work. Dr. Askenazi reported receiving personal fees from Baxter, Nuwellis Inc., Medtronic, SeaStar, and BioPorto, and financial support for research from Zorro-Flow outside the submitted work; in addition, Dr. Askenazi reported having a patent for Zorro-Flow, an external urine collection device pending, and a patent for continuous renal replacement therapy (CRRT) advancements pending. Dr. Bagshaw reported receiving personal fees from Baxter and BioPorto during the conduct of the study. Dr. Barreto reported receiving financial support for research from FAST Biomedical Consultant and Wolters-Kluwer Consultant outside the submitted work. Dr. Brophy reported receiving personal fees from UpToDate, during the conduct of the study, and American Board of Medical Specialities finance board. Dr. Charlton reported receiving personal fees from Medtronics Carpediem Clinical Events Committee outside the submitted work. Dr. Devarajan reported receiving grants from National Institutes of Health/National Institute of Diabetes and Digestive and Kidney Diseases during the conduct of the study; holding a patent as co-inventor on patents licensed to Abbott Diagnostics and BioPorto Inc., on use of neutrophil gelatinase-associated lipocalin as a biomarker of kidney injury. Dr. Gist reported receiving financial support for research from Medtronic Speaker Honorarium and financial support for research from BioPorto Diagnostics consulting fees outside the submitted work. Dr. Menon reported receiving personal fees from Nuwellis Inc. outside the submitted work. Dr. J. Morgan reported receiving personal fees from Medtronic Consultant outside the submitted work. Dr. Mottes reported receiving financial support for research from Medtronic outside the submitted work. Dr. Stanski reported receiving grants from National Center for Advancing Translational Sciences of the National Institutes of Health Institutional CT2 grant, 2UL1TR001425-05A1 and travel reimbursement from pADQI Travel funds to travel to consensus meeting (flight and hotel) during the conduct of the study; in addition, Dr. Stanski reported holding a patent for PERSEVERE-II AKI Prediction Model pending. Dr. Zappitelli reported receiving financial support for research from BioPorto Inc. adjudicator/consultant for a study on neutrophil gelatinase-associated lipocalin and financial support for research from Baxter Inc. Honorarium for a national talk on CRRT (not viewed by company ahead of time) outside the submitted work. Dr. Kellum reported receiving personal fees from Dialco; being an employee of Spectral Medical and its wholly owned subsidiary Dialco outside the submitted work; and paid consultant for Astute Medical. Dr. Ostermann reported receiving grants from Fresenius Research funding, grants from Baxter Research funding, and grants from bioMerieux Research funding during the conduct of the study. Dr. Basu reported receiving personal fees from BioPorto Diagnostics outside of the submitted work and personal fees from bioMerieux outside of the submitted work. During the conduct of the study, in addition, Dr. Basu reported having a patent for Renal Angina Index pending outside of the submitted work, and a patent for olfactomedin-4 pending outside of the submitted work. No other disclosures were reported.